Company Overview of Intrexon Corporation
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and clon...
20374 Seneca Meadows Parkway
Germantown, MD 20876
Founded in 1998
Key Executives for Intrexon Corporation
Chairman and Chief Executive Officer
Total Annual Compensation: $4.4M
Chief Financial Officer
Total Annual Compensation: $785.5K
Senior Vice President of Finance
Total Annual Compensation: $315.4K
Chief Communications Officer and Senior Vice President
Total Annual Compensation: $238.7K
Total Annual Compensation: $879.2K
Compensation as of Fiscal Year 2015.
Intrexon Corporation Key Developments
Intrexon Corporation Announces the Formation of Wholly-Owned Subsidiary, Precigen, Inc; Announces Executive Changes
Mar 10 17
Intrexon Corporation announced the formation of Precigen Inc., a wholly-owned subsidiary of the company as part of an ongoing evaluation of structural alternatives concerning its business in healthcare. Intrexon currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic options to enhance shareholder value. Through utilization of Intrexon's proprietary technology platform, gene and cell therapy candidates in an array of therapeutic areas including oncology, rare diseases, infectious diseases, ophthalmology, and cardiovascular disease are under development or have completed development. Precigen will encompass all of Intrexon's health related collaborations, including its Exclusive Channel Collaborations and Research Collaborations, Joint Ventures and its 75% ownership stake in its Xogenex subsidiary.
Intrexon also announced that Geno Germano is stepping down as President, and Randal Kirk has cancelled plans to transition to Executive Chairman and will remain Chairman and CEO. Intrexon has a search underway for an executive to lead Precigen.
Intrexon Looking At Strategic Options
Mar 10 17
Intrexon Corporation (NYSE:XON) currently intends to consolidate all health-related assets under a new corporate entity as it considers potential strategic options to enhance shareholder value. "While we have been reviewing potential options for over a year, as our collaborators increasingly begin to move into the clinic, it is apparent that our collection of health assets may be overshadowed by the breadth and complexity of the opportunities the engineering of biology has afforded us. We are therefore taking this structural action now to better position us for strategic decisions regarding our health business moving forward," said Randal J Kirk, Chairman and Chief Executive Officer. "Notably this structural move will have no impact on the programs of our collaborations in health or the pipeline of clinical stage product candidates."
Intrexon Corporation Announces Appointment of Andy Bass as Senior Vice President, Consumer Sector
Mar 6 17
Intrexon Corporation announced the appointment of Andy Bass as Senior Vice President, Consumer Sector, which will henceforth do business as BioPop. Andy will lead the design and commercialization of new biologically-based products and applications across consumer markets using Intrexon's powerful platforms and expertise for engineering biology. Andy brings extensive experience in life sciences and consumer product development to Intrexon. Most recently he co-founded and served as Chief Executive Officer of Biological & Popular Culture Inc. (BioPop), now a wholly owned subsidiary of Intrexon and a consumer biotechnology company selling products in more than 20 countries.
Similar Private Companies By Industry
Recent Private Companies Transactions